Biohaven Ltd (N:BHVN)

Business Focus: Biotechnology & Medical Research

Jan 08, 2024 06:30 am ET
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therap
Five proprietary platforms fueling multiple clinical programsTargeting large indications including epilepsy, bipolar disorder, depression, obsessive-compulsive disorder, migraine, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Plus, rare autoimmune and inflammatory diseases, including myasthenia gravis, cardiomyopathy, spinal muscular atrophy and IgA nephropathyNEW HAVEN, Conn. and SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a clinical-stage biopharmaceutical company focused
Jan 02, 2024 06:00 am ET
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW HAVEN, Conn., Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 8, 2024 at 8:15 am (PT).
Dec 01, 2023 03:30 pm ET
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses studied without the typical central nervous system (CNS) adverse effects associated with other anti-seizure medications (ASMs), such as somnolence and cognitive/mood disturbances.In a Phase 1 electroencephalogram (EEG) biomarker study, BHV-7000 demonstrated dose-dependent target engagement in the brain as measured by changes in EEG spectral power across all brain regions.Additional poster presentations at the American Epilepsy Society Annua
Nov 14, 2023 03:05 pm ET
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023, which included net proceeds of $242 million from completed public offering on October 5, 2023Completed public offering of 11,761,363 Biohaven Ltd. common shares, which included the exercise in full of the underwriters' option to purchase additional shares, at a price to the public of $22.00 per shareAnnounced important updates on the Company's immunology and extracellular protein degradation platform:Immunoglobulin G (IgG) degrader BHV-1300 demonstrated IgG reductions of g
Oct 16, 2023 07:00 am ET
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including obesity.
Oct 05, 2023 04:05 pm ET
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW HAVEN, Conn., Oct. 5, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closing of its underwritten public offering of 11,761,363 of its common shares, which includes the full exercise of the underwriters' option to purchase 1,534,090 additional common shares, at a public offering price of $22.00 per share. The gross proceeds from the offering were approximately $258.7 million before
Oct 02, 2023 11:56 pm ET
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
NEW HAVEN, Conn., Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 10,227,273 of its common shares at a price to the public of $22.00 per share.  In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 1,534,090 common shares at the public offering price, less underwriting discounts and com
Oct 02, 2023 04:36 pm ET
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
NEW HAVEN, Conn., Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has commenced an underwritten public offering of $200 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an additional $30 million of common shares at the public
Sep 14, 2023 07:00 am ET
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
- Taldefgrobep alfa is the only myostatin inhibitor in clinical development that targets both myostatin and activin A signaling, two key regulators of muscle mass and adipose tissue
Aug 02, 2023 06:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Jul 31, 2023 09:31 am ET
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
Taldefgrobep alfa, in Phase 3 global clinical development for Spinal Muscular Atrophy, granted EU Orphan Drug Designation in addition to previously receiving Fast Track and Orphan Drug Designation in the USNEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN; "Biohaven") announced today that it received orphan medicinal product designation from the European Commission (EC) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA). Orphan Designation highlights the potential for taldefgrobep to deliver significant benefit f
Jul 31, 2023 06:59 am ET
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disordersBrain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to dateBiohaven anticipates initiating a
Jul 27, 2023 07:00 am ET
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
NEW HAVEN, Conn., July 27, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced multiple updates on key programs including: preliminary EEG data from its lead investigational agent, BHV-7000, from the Kv7 activator program; Phase 1 update on its brain-penetrant dual TYK2/JAK1 inhibitor, BHV-8000; development update on its IgG degrader, BHV-1300, from the bispecific
May 31, 2023 07:00 am ET
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
Submitted a new drug application (NDA) for troriluzole in Spinocerebellar Ataxia Type 3 (SCA3) to U.S. FDA in 2Q2023, marking the team's fourth NDA in approximately 3 yearsReleased additional data from Kv7 platform, including Phase 1 safety data by dose groups for BHV-7000 that further validates differentiated profileProjected Phase 3 Spinal Muscular Atrophy trial to complete enrollment in 2023Initiated Phase 1 study of brain penetrant TYK2/JAK1 inhibitor, BHV-8000, and anticipate beginning Phase 2 trial in Parkinson's disease next yearHighlighted robust pipeline with multiple INDs planned t
May 25, 2023 05:00 pm ET
Biohaven to Present R&D Day at Yale School of Management
NEW HAVEN, Conn., May 25, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating diseases, including ultra-rare disorders, will provide an overview of its platforms and pipeline at an in-person Research and Development (R&D) Day taking place on May 31 in New Haven, CT, concurrently with the Yale Ventures Innovation Summit 2023. Members of Biohaven's senior management team and key opinion leaders will be meeting with i
May 12, 2023 04:30 pm ET
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epileps
Apr 17, 2023 07:00 am ET
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
NEW HAVEN, Conn., April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy.  
Mar 23, 2023 04:05 pm ET
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China) rights; Phase 1 clinical trial initiation anticipated in 2023Completed Phase 1 SAD/MAD study with BHV-7000 from our Kv7 ion channel activator platform and reported preliminary safety and tolerability dataCommenced enrollment in pivotal Phase 3 study with our myostatin targeting agent, adnectin taldefgrobep alfa, for spinal muscular atrophyPresented preclinical data from our IgG degrader, BHV-1300, showing robust reduction of IgG levels; o
Mar 22, 2023 07:30 am ET
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (
Mar 14, 2023 07:30 am ET
Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
BHV-7000 differs pharmacologically and structurally from other known Kv7 compounds in developmentBHV-7000 demonstrates potent anti-seizure activity without effects on neurobehavior in preclinical modelsBHV-7000 CNS side effect profile in Phase 1 compares favorably to anti-seizure medications currently approved and in clinical development   NEW HAVEN, Conn., March 14, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it will present an oral and poster presentation demonstrating the preclinical efficacy and initial Phase 1 safety and tolerability of BHV-7000, a novel activat
Jan 06, 2023 06:30 am ET
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
NEW HAVEN, Conn., Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 10, 2023 at 7:30 am (PT).
Nov 09, 2022 06:00 am ET
Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
Biohaven Ltd. launched post-closing of the Biohaven Pharmaceutical Holding Company Ltd. sale to Pfizer on October 4, 2022, and completed a public offering of 28,750,000 Biohaven Ltd. common shares at a price of $10.50 per share on October 25, 2022, with a total initial capitalization and net cash proceeds from offering of approximately $541 million, and no debt.Advancing multiple late-stage clinical programs including innovative drug candidates targeting Kv7 modulation for epilepsy and neuropsychiatric disorders, glutamate modulation in Obsessive-Compulsive Disorder (OCD) and spinocerebellar
Oct 25, 2022 08:21 pm ET
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW HAVEN, Conn., Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (the "Company" or "Biohaven") today announced the closing of an underwritten public offering of 28,750,000 of its common shares, which includes the full exercise of the underwriters' option to purchase 3,750,000 additional shares, at the public offering price of $10.50 per share. The gross proceeds raised in the offering, before deducting underwriting discounts and estimated expenses of the offering payable by Biohaven, were approximately $301.9 million.
Oct 25, 2022 04:30 pm ET
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including neuroscience, immunology and oncologyThrough its continued collaboration with Yale University in the laboratory of Professor David Spiegel and Biohaven Labs, Biohaven has made further innovations in this ground-breaking technology with new patent applications covering additional targets and functionalityIn-licensed from Yale University in 2021, the MoDE platform is based on patent applications filed by Yale in 2018 and 2019NEW HAVEN, Conn., Oct.
Oct 20, 2022 10:30 pm ET
Biohaven Announces Pricing of Public Offering of Common Shares
NEW HAVEN, Conn., Oct. 20, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven") announced today the pricing of the public offering of 25,000,000 of its common shares, at a public offering price of $10.50 per common share. Biohaven has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 common shares. The offering is expected to close on October 25, 2022, subject to the satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.
Oct 18, 2022 04:12 pm ET
Biohaven Announces Launch of Public Offering of Common Shares
NEW HAVEN, Conn., Oct. 18, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven") announced today that it has commenced a public offering of 20,000,000 of its common shares pursuant to a registration statement on Form S-1 (the "Registration Statement") filed with the Securities and Exchange Commission (the "SEC"). Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.
Oct 04, 2022 07:30 am ET
Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients
Broad therapeutic research and development portfolio includes more than 13 clinical and pre-clinical programs with a focus on neuroscience and rare disorders including epilepsy, pain and mood disorders, obsessive compulsive disorder (OCD), spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA).Excitement mounting for clinical stage neuroscience program in Kv7 Ion Channel Modulation which targets key subunits involved in neuronal signaling and plays a critical role in regulating the hyperexcitable state in epilepsy and potentially other central nervous system (CNS) disorders. Biohaven
Oct 03, 2022 01:01 pm ET
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
Sep 29, 2022 08:00 am ET
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
NEW HAVEN, Conn., Sept. 29, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of treatment with verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS). The HEALEY ALS Platform Trial, the first-ever platform trial in ALS, is designed as an adaptive trial to evaluate multiple investigational treatments simultaneously, thus accelerating the development of effective and breakthrough treatments for people living with ALS.
Sep 18, 2022 07:42 pm ET
Biohaven Announces Record Date for Anticipated Spin-Off
NEW HAVEN, Conn., Sept. 18, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has set a record date of September 26, 2022 (the "Record Date") for the previously announced spin-off by Biohaven of its Biohaven Ltd. ("SpinCo") subsidiary, which will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Biohaven. The completion of the spin-off remains subject to closing conditio
Sep 06, 2022 09:00 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, DRE, PLD, GMTX, SAFE
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Aug 31, 2022 07:00 am ET
Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
Results from this study demonstrate a robust and clinically meaningful reduction in barbiturate use after the initiation of Nurtec ODT, providing an alternative migraine therapy for those who may be reliant on butalbital or desire an alternative therapy that is not associated with addiction potential.Despite being associated with addiction potential, medication overuse (rebound) headaches and central nervous system side effects, barbiturates are prescribed as first-line migraine treatments.Longitudinal medical and prescription claims were used to assess barbiturate prescriptions and mean mil
Aug 29, 2022 09:00 am ET
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, VIVO, HNGR
NEW YORK, Aug. 29, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Aug 25, 2022 05:17 pm ET
The M&A Class Action Firm Continues Investigating the Merger – BHVN, ONEM, GBT, CDEV
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 15, 2022 09:00 am ET
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Aug 05, 2022 07:00 am ET
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously announced Pfizer Inc. acquisition of Biohaven Pharmaceutical Holding Company Ltd.; preliminary proxy statement has been filed with the SECNURTEC® ODT (rimegepant) TRx volumes grew 11% and net product revenue was $194 million, up sequentially 57%Anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share; n
Aug 03, 2022 10:23 am ET
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates COWN, SWIR, BHVN, GLTA
NEW YORK, Aug. 3, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 28, 2022 07:30 am ET
American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other
84% of people with migraine (PwM) and 92% of healthcare professionals (HCPs) agree that worsening migraine leads to poorer mental health Nearly all HCPs (93%) feel mental health impacts a PwM's ability to successfully manage their migraine77% of PwM worry about stigma of migraine and mental health and are hesitant to discuss with their HCP MOUNT ROYAL, NJ, July 28, 2022 /PRNewswire/ -- The American Migraine Foundation (AMF) and Biohaven Pharmaceuticals (NYSE: BHVN) today announced findings from a new survey about migraine and its impact on mental health. The results of the Migraine and Menta
Jul 27, 2022 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HMTV, BHVN, CMAX, VMW
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hemisphere Media Group, Inc. (NASDAQ:...
Jul 26, 2022 02:06 pm ET
The M&A Class Action Firm Continues Investigating the Merger
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 26, 2022 02:50 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HMTV, BHVN, DRE, PLD
NEW YORK, July 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 13, 2022 12:48 pm ET
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, GRRB, SIMO, MN
NEW YORK, July 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 06, 2022 01:00 pm ET
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven's troriluzole and Vigeo's VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – t
Jun 28, 2022 11:16 am ET
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, USWS, HR, SREV
NEW YORK, June 28, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 22, 2022 01:14 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, HMTV, SIMO, SREV
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical Holding...
Jun 20, 2022 09:00 am ET
SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates BHVN, HMTV, SIMO, SREV
NEW YORK, June 20, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 18, 2022 07:16 pm ET
Lifshitz Law PLLC Announces Investigation of EMCF, FSI, BHVN, and RTLR
Emclaire Financial Corp. (NASDAQ: EMCF) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of EMCF to Farmers National Banc Corp. Pursuant to the terms of the merger agreement, EMCF...
Jun 15, 2022 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MUDS, EMCF, FSI, BHVN
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mudrick Capital Acquisition...
Jun 14, 2022 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates BHVN, SWCH, TREC, CTEK
NEW YORK, June 14, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 13, 2022 07:04 pm ET
Lifshitz Law PLLC Announces Investigation of EMCF, FSI, BHVN, and RTLR
Emclaire Financial Corp. (NASDAQ: EMCF) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of EMCF to Farmers National Banc Corp. Pursuant to the terms of the merger agreement, EMCF...
Jun 13, 2022 07:30 am ET
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Za
-  Nurtec ODT open-label extension study is the first of its kind evaluating a CGRP-targeted medication in patients who are using it as a preventive and an as-needed acute treatment for migraine-  Over the course of this open-label extension study, > 80% of patients experienced ≥50% reduction and approximately 50% experienced a 100% reduction -  Complete data from the Phase 3 zavegepant nasal spray study highlight its ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single dose -  New studies showed positive efficacy, safety and pharmacokinetics data
Jun 09, 2022 09:37 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates BHVN, EMCF, HR, FSI
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical Holding...
Jun 09, 2022 07:30 am ET
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Heada
31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR dataLate-breaking submissions showcase new data for Nurtec ODT in Chinese and Korean patients and patterns of medication utilization in adults using it as an acute and preventive treatmentResults from long-term studies of Nurtec ODT as a preventive and acute treatment of migraine showed more than 80% of patients achieved ≥50% reduction in moderate or severe monthly migraine days and approximately half experienced a 100% reductionOther oral pre
Jun 06, 2022 09:00 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLP Investigates HMTV, BHVN, MANT, SWCH
NEW YORK, June 6, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 31, 2022 05:51 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, SWCH
NEW YORK, May 31, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 28, 2022 08:05 pm ET
Lifshitz Law PLLC Announces Investigation of EMCF, FSI, BHVN, and RTLR
Emclaire Financial Corp. (NASDAQ: EMCF) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of EMCF to Farmers National Banc Corp. Pursuant to the terms of the merger agreement, EMCF...
May 25, 2022 09:00 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, SWCH, MICT
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical Holding...
May 24, 2022 06:02 pm ET
Lifshitz Law PLLC Announces Investigation of EMCF, FSI, BHVN, and RTLR
Emclaire Financial Corp. (NASDAQ: EMCF) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of EMCF to Farmers National Banc Corp. Pursuant to the terms of the merger agreement, EMCF...
May 23, 2022 09:00 am ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates BHVN, SWCH, TREC, MICT
NEW YORK, May 23, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 23, 2022 07:30 am ET
US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine
If approved, zavegepant nasal spray would be the only FDA-approved CGRP receptor antagonist in an intranasal formulation, giving patients a new treatment option that provides ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single doseZavegepant nasal spray may provide an important alternative for patients who need a quick onset of action or those who cannot take oral treatments due to nausea and vomiting at the time of migraine onsetNEW HAVEN, Conn. , May 23, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced
May 23, 2022 07:15 am ET
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
NEW HAVEN, Conn., May 23, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with spinocerebellar ataxia (SCA). The primary endpoint, change from baseline to Week 48 on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA), did not reach statistical significance in the overall SCA population as there was less than expected disease progression over the course of the study. In the overall
May 17, 2022 04:39 pm ET
May 17, 2022 01:49 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BHVN, SWCH, TREC
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical Holding...
May 17, 2022 11:32 am ET
BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Biohaven will receive only $148.50 in cash and 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven’s non-CGRP development stage pipeline compounds, for each share of Biohaven that they own. KSF is seeking to determine whether this consideration and the process th
May 16, 2022 09:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BHVN, SWCH, TREC, SAIL
NEW YORK , May 16, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 13, 2022 10:19 pm ET
Shareholder Alert - The M&A Class Action Firm Announces an Investigation of BioHaven Pharmaceutical Holding Company Ltd. - BHVN
NEW YORK, May 13, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating BioHaven Pharmaceutical Holding Company Ltd. (BHVN), relating to its proposed merger with Pfizer Inc. Under the terms of the agreement, BHVN shareholders will receive 0.5 shares of New Biohaven and $148.50 in cash per share. Click here for
May 11, 2022 10:18 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PSB, SREV, HMTV, BHVN
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PS Business Parks, Inc. (NYSE: PSB)’s...
May 10, 2022 11:05 pm ET
BIOHAVEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd.
NEW ORLEANS, May 10, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to Pfizer Inc. (NYSE: PFE).  Under the terms of the proposed transaction, shareholders of Biohaven will receive only $148.50 in cash and 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's non-CGRP development stage pipeline compounds, for each share of Biohaven that they own. KSF is seeking to determ
May 10, 2022 05:47 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Biohaven Pharmaceutical Holding Company Ltd. (NYSE - BHVN), Tiga Acquisition Corp. (NYSE - TINV), Lakeshore Acq
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
May 10, 2022 05:16 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.
NEW YORK, May 10, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE). Under the terms of the merger agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven p
May 10, 2022 04:58 pm ET
BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BHVN and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) breached their fiduciary duties or...
May 10, 2022 11:49 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BHVN, TINV, SREV, HMTV, TEN
NEW YORK , May 10, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 10, 2022 09:49 am ET
BHVN Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Biohaven Pharmaceutical to Pfizer
The law firm of Wohl & Fruchter LLP is investigating whether the directors of Biohaven Pharmaceutical Holding Company, Ltd. (ticker: BHVN) (“Biohaven”) acted in the best interests of Biohaven shareholders in approving the sale of Biohaven to Pfizer...
May 10, 2022 08:27 am ET
BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to Pfizer Inc. for $148.50 per share in cash is fair to Biohaven shareholders. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven’s non-CGRP development stage pipeline compounds, per Biohaven common share.
May 10, 2022 06:50 am ET
Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments
Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. today announced that the companies have entered into a definitive agreement under which Pfizer will acquire BiohavenRecord reported revenues of $319 millionNURTEC® ODT (rimegepant) TRx volumes grew 8% versus the fourth quarter and net product revenue was $124 million for the first quarter of 2022Net product sales guidance of $825 - $900 million provided for 2022Received EU approval from the European Commission ("EC") for rimegepant 75 mg for the acute and preventive treatment of migraine; EC marketing authorization valid in all 27
May 10, 2022 06:45 am ET
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adult
May 09, 2022 07:30 am ET
Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022
NEW HAVEN, Conn., May 9, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, plans to hold its upcoming first quarter 2022 earnings call and webcast, reporting financial results for the quarter ended March 31, 2022, and provide a review of recent accomplishments and anticipated upcoming milestones, on Wednesday, May 11, 2022 at 8:30 a.m. ET.   The earnings call and webcast will follow Biohaven's issuance o
Apr 27, 2022 06:45 am ET
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month. VYDURA®, an orally disintegrating tablet, is the first medicine approved for both acute and prophylactic treatment of migraine in the European Union (EU). Mig
Apr 14, 2022 04:30 pm ET
Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability
More than 25% of patients reported being severely or very severely impacted by their migraine attacksStudy showed higher levels of migraine-related disability were associated with increased HCRU costs in primary care and specialty settings among adults with episodic migraineData suggests that assessment of disability in people with migraine may support prescribing of cost-effective interventions, particularly among those with severe disabilityNEW HAVEN, Conn., April 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the publication of new real-world
Apr 14, 2022 07:30 am ET
Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update
- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels
Apr 07, 2022 07:30 am ET
Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis
Longitudinal medical and prescription claims were used to assess opioid prescriptions and MME's dispensed amongst migraine patients nine months prior to and nine months following Nurtec® ODT initiation.  Among the 14,019 with migraine who used opioids prior to initiating treatment with Nurtec ODT, approximately 41% had no opioid Rx fills in the 9 months following initiation.  Results demonstrate a clinically meaningful reduction in opioid use in this patient population and may be of benefit to those reliant on opioids to manage their disease, thereby alleviating potential negative consequenc
Apr 06, 2022 07:30 am ET
Biohaven Expands Commitment to Supporting Veterans and Military Through Sole Sponsorship of National Headache Foundation's (NHF) Outreach Program
NHF's Veterans/Military Outreach Program aims at raising awareness of migraine in this high-risk populationSponsorship adds to existing Biohaven programs supporting active-duty service members, veterans and their families with migraineNEW HAVEN, Conn., April 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it is the sole sponsor of the National Headache Foundation's (NHF) Veterans/Military Outreach program which aims to raise awareness about migraine, elevate the discussion about the disease among active-duty military and veterans, and in
Apr 01, 2022 07:30 am ET
Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal
NEW HAVEN, Conn., April 1, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that data from a Phase 1, single-center, open-label study evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women was published in the peer-reviewed journal, Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine.
Mar 31, 2022 07:30 am ET
Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases
Migraine patients treated with Nurtec ODT had a reduction in total opioid prescriptions filled after initiation of therapy, according to an analysis of real-world administrative claimsSingle and multiple daily doses of intranasal zavegepant of up to 40 mg were well tolerated in Phase 1 studyRimegepant, atogepant and monoclonal antibody treatments determined to be effective options for the prevention of migraine when compared vs placeboNEW HAVEN, Conn., March 31, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 13 abstracts, including two or
Feb 25, 2022 06:00 am ET
BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS
NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a review of accomplishments during 2021 and anticipated upcoming milestones.
Feb 25, 2022 05:59 am ET
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
NEW HAVEN, Conn. and NEW YORK, Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, recommending the 75 mg dose of rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic mi
Feb 25, 2022 05:55 am ET
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences
NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") announced today that it has entered into a definitive agreement to acquire Channel Biosciences, LLC, a subsidiary of Knopp Biosciences LLC, and its Kv7 channel targeting platform – adding the latest advances in ion-channel modulation to Biohaven's growing neuroscience portfolio. The Kv7 platform has been developed and refined for over a decade by a team with deep experience in ion channel science led by Michael Bozik, M.D., and Steven Dworetzky, Ph.D. Both le
Feb 25, 2022 05:50 am ET
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that it entered into a worldwide license agreement with Bristol Myers Squibb (NYSE: BMY) for the development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin. Taldefgrobep is the third development asset licensed to Biohaven from Bristol Myers Squibb and a clinical trial for Spinal Muscular Atrophy (SMA) is expected to begin in 2022.
Feb 22, 2022 06:30 am ET
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
NEW HAVEN, Conn., Feb. 22, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has commenced enrollment in a Phase 2/3 clinical trial assessing the efficacy and safety of Nurtec® ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis (CRS) with or without nasal polyps.
Feb 16, 2022 06:30 am ET
BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022
NEW HAVEN, Conn., Feb. 16, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming fourth quarter and year end 2021 earnings call and webcast, reporting financial results for the quarter ended December 31, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones, on Friday February 25, 2022 at 8:30 a.m. ET.
Feb 14, 2022 06:00 am ET
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
NEW HAVEN, Conn. and NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced positive top-line results from an Asia-Pacific, Phase 3 clinical trial of rimegepant in 1,431 adults for the acute treatment of migraine. Led by BioShin Limited, a subsidiary of Biohaven in China and South Korea, the randomized, regional, multi-center study met the co-primary endpoints evaluating the efficacy and safety of the orally dissolving tablet (ODT) formulation of rimegepant, an oral calcitonin gene-related peptide (CGRP)
Feb 12, 2022 11:00 am ET
Hardware LDN Debuts Fall/Winter 2022 Collection
NEW YORK, Feb.12, 2022 /PRNewswire/ -- Heating up the runway this winter, Jessica Horwell makes a return to New York Fashion Week, captivating the city with her signature execution of sexy elegance. An experimental play on mixed materials and pops of color elevates Hardware LDN's quintessential style of grunge and glamour.
Feb 03, 2022 06:30 am ET
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports
NEW HAVEN, Conn., Feb. 3, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the publication of new findings from its long-term safety study showing reductions in migraine frequency in patients treated with rimegepant 75 mg for the acute treatment of migraine in the February issue of Cephalalgia Reports. Cephalalgia Reports is a medical-neurological journal in the field of headache research and is an official journal of the International Headache Society.
Jan 09, 2022 11:01 pm ET
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain
NEW HAVEN, Conn. and LEUVEN, Belgium, Jan. 10, 2022 /PRNewswire/ -- Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven, announced today that they have entered into an exclusive global license and research agreement to develop and commercialize first-in-class TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LIC
Jan 06, 2022 06:00 am ET
BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY
NEW HAVEN, Conn., Jan. 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the fourth quarter of 2021. 
Jan 05, 2022 06:00 am ET
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
NEW HAVEN, Conn. and NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two companies. The transaction agreements, including Pfizer's commercialization of rimegepant and zavegepant outside of the U.S., have become effective following the receipt of required regulatory approvals and the satisfaction of other customary conditions, and BHVN shares have been issued to Pfizer. Biohaven will continue to lead research and development gl
Dec 13, 2021 06:00 am ET
BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE
NEW HAVEN, Conn., Dec. 13, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that NURTEC ODT (rimegepant) 75 mg was approved by the Ministry of Health of Israel for the preventive treatment of episodic migraine in adults. NURTEC ODT is also approved in Israel for the acute treatment of migraine with and without aura in adults. Registration in Israel is the first approval for NURTEC ODT for the preventive treatment indication outside the United States.
Dec 06, 2021 06:30 am ET
Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application
NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from the second pivotal clinical trial (NCT04571060) evaluating the safety and efficacy of its investigational therapy, intranasal zavegepant, for the acute treatment of migraine in adults. The Phase 3 study achieved its co-primary regulatory endpoints of pain freedom and freedom from most bothersome symptom at 2 hours and showed broad efficacy by demonstrating statistically significant superiority to placebo across a total of 15 prespecified prima
Dec 06, 2021 06:29 am ET
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of commercial and innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately. The company also announced the appointment of Matthew Buten to the role of Chief Financial Officer (CFO) effective by December 20,
Nov 18, 2021 07:30 am ET
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease
Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, and Biohaven Therapeutics Ltd. (“Biohaven”, parent company NYSE:BHVN), a commercial-stage Neuroinnovation company, today announced the...
Nov 17, 2021 05:57 am ET
NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine
NEW HAVEN, Conn., Nov. 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that NURTEC® ODT (rimegepant) was approved by the Kuwait Ministry of Health for the acute treatment of migraine with and without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.
Nov 15, 2021 07:00 am ET
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital
NEW HAVEN, Conn., Nov. 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that enrollment is now complete in the verdiperstat arm of the HEALEY ALS Platform Trial. This first-ever platform trial in ALS, sponsored by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), is designed to evaluate the safety and efficacy of multiple drug candidates in people with Amyotrophic Lateral Sclerosis ("ALS"). Verdiperstat was selected as one of the inaugural investigational treatments for the HEALEY ALS Plat
Nov 09, 2021 06:46 am ET
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval.  Rimegepant is commercialized as Nurtec® ODT in the U.S., and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. An application for the approval of rimegepant is currently under review by the European Medicines Agency and several addit
Nov 09, 2021 06:45 am ET
Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments
NEW HAVEN, Conn., Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today reported financial results for the third quarter ended September 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
Nov 04, 2021 07:30 am ET
Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021
NEW HAVEN, Conn., Nov. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming third quarter 2021 earnings call and webcast, reporting financial results for the quarter ended September 30, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones, on Tuesday November  9, 2021 at 8:00 a.m. ET.
Nov 02, 2021 07:30 am ET
Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans Ahead of 80th Anniversary at Phoenix Raceway
MOORESVILLE, N.C., Nov. 2, 2021 /PRNewswire/ -- Rick Ware Racing (RWR) has joined forces once again with Nine Line Apparel and Biohaven Pharmaceuticals' Nurtec® ODT (rimegepant) to pay tribute and honor the upcoming 80th Anniversary of the Attack on Pearl Harbor this weekend at Phoenix Raceway for the season finale.
Oct 27, 2021 07:30 am ET
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
NEW HAVEN, Conn., Oct. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced the enrollment of the first patient in a Phase 1a/1b trial in Multiple Myeloma using the ARM, BHV-1100, in combination with autologous cytokine induced memory-like (CIML) natural killer (NK) cells and immunoglobulin (Ig) to target and kill multiple myeloma cells expressing the cell surface protein CD38 (Figure 1). BHV-1100 is the lead clinical asset from Biohaven's ARM Platform, developed from a strategic alliance with PeptiDream Inc. This clinical trial will assess the safety
Oct 05, 2021 07:30 am ET
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
NEW HAVEN, Conn., Oct. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the third quarter of 2021. 
Sep 27, 2021 07:00 am ET
Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program
NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of a clinical trial of verdiperstat in multiple system atrophy (MSA).  Verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy measure, nor on the key secondary efficacy measures. Initial analysis of safety data was consistent with the overall profile of verdiperstat from prior clinical trial experience. Additional analyses are still pending, and full study results will be presented at an upcoming
Sep 09, 2021 07:30 am ET
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Fe
NEW HAVEN, Conn., Sept. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 17 abstracts, including three late-breaking presentations and four oral presentations, will be shared at the 2021 International Headache Society – European Headache Federation Joint Congress virtually from September 8-12, 2021.
Aug 09, 2021 07:00 am ET
Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments
NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today reported financial results for the second quarter ended June 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
Jul 29, 2021 07:30 am ET
Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race
NASHVILLE, Tenn., July 29, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today Nurtec® ODT (rimegepant) is the official migraine partner of the Big Machine Music City Grand Prix. Romain Grosjean of Rick Ware Racing will pilot the No. 51 NTT INDYCAR Series Nurtec ODT Honda for this inaugural event, which will be held on the streets of Nashville, Tenn. on August 8, 2021. Nurtec ODT is the first and only medication that's proven to both treat and prevent migraine attacks.
Jul 28, 2021 07:30 am ET
Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202
NEW HAVEN, Conn., July 28, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming second quarter 2021 earnings call and webcast, reporting financial results for the quarter ended June 30, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones, on Monday August 9, 2021 at 8:30 a.m. ET.
Jul 07, 2021 07:00 am ET
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
NEW HAVEN, Conn., July 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the second quarter of 2021. 
Jun 23, 2021 03:00 am ET
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
TOKYO and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study. HTL0022562 (also known as BHV3100) is a novel, small molecule CGRP* receptor antagonist discovered by Sosei Heptares and the lead compound in a portfolio of CGRP antagonists licensed to Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven", NYSE: BHVN) in December 2020 for development as new therapies for CGRP-mediated disorders.
Jun 17, 2021 04:01 pm ET
Biohaven Appoints Kishen Mehta to Board of Directors
NEW HAVEN, Conn., June 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of Kishen Mehta, Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors ("Board"). Mr. Mehta previously served as a strategic advisor to Biohaven.
Jun 08, 2021 12:35 pm ET
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals (NYSE: BHVN) ringing the opening bell, June 8, 2021. BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine.
Mar 01, 2021 04:00 pm ET
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
Artizan Biosciences, Inc. (“Artizan”), a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota, today announced the company has raised $11 million in a Series A-2 financing led by existing...
Feb 23, 2021 05:40 pm ET
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021
NEW HAVEN, Conn., Feb. 23, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will host a conference call and webcast to report fourth quarter and full year 2020 financial results and provide a review of recent accomplishments and anticipated upcoming milestones, on Monday March 1, 2021 at 8:30 a.m. ET.
Feb 22, 2021 06:30 am ET
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
NEW HAVEN, Conn., Feb. 22, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced that a hyperimmune globulin mimic (HGM) developed with Biohaven's proprietary MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including the strains known as the "English" and "South African" variants (also known as B.1.1.7 and B.1.351, respectively). The preliminary experiments, conducted by Biohaven Labs and an academi
Feb 08, 2021 06:30 am ET
Biohaven Provides Update On ESG Practices
NEW HAVEN, Conn., Feb. 8, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the advancement of several important steps that underscore the company's commitment to sound Environmental, Social and Governance ("ESG") practices.
Jan 25, 2021 06:30 am ET
Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT
NEW HAVEN, Conn., Jan. 25, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the fourth quarter of 2020. 
Jan 18, 2021 09:10 am ET
Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season
MOORESVILLE, N.C., Jan. 18, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Cody Ware will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing during the 2021 NASCAR Cup Series season. The first race of the season with Cody behind the wheel is the DAYTONA 500, at Daytona International Speedway on February 14.
Jan 18, 2021 08:00 am ET
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
NEW HAVEN, Conn., Jan. 18, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD). Additional secondary and exploratory efficacy analyses and biomarker data including neurofilament light chain (NfL), neurogranin, tau and amyloid are still pending and expected in the coming months.
Jan 07, 2021 06:30 am ET
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ("Kleo") that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo's laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve as the in
Jan 05, 2021 09:00 am ET
Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry
MOORESVILLE, N.C., Jan. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona. Biohaven joins Eurasia Motorsports and BAM Motorsports Management as the primary partner for the premier event. The 24-hour sports car endurance race is held annually at Daytona International Speedway in Daytona Beach, Florida, and is the first major automobile race of the year. Former Daytona 500 Champion Austin Dillon, and 2019-2020 Asian Le Mans Ser
Jan 04, 2021 06:30 am ET
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
NEW HAVEN, Conn., Jan. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive disorder (OCD). Biohaven is advancing the 280 mg once daily dose of troriluzole into two double-blind, placebo-controlled Phase 3 clinical trials with identical study designs and plans to enroll approximately 600 patients in each of these adjunctive treatment trials across study sites in both the United States and
Dec 16, 2020 06:30 am ET
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
NEW HAVEN, Conn., Dec. 16, 2020 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that The Lancet published the company's positive results from a Phase 3 clinical trial of rimegepant for the preventive treatment of migraine in adults. These data show rimegepant was superior to placebo in the reduction of monthly migraine days. Rimegepant was approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in February 2020.  Rimegepant is marketed as NURTEC® ODT, and is the first and only calcitonin gene-related peptide (CGRP
Dec 07, 2020 10:00 am ET
Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific molecule...
Dec 02, 2020 09:05 am ET
Biohaven's Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series
MOORESVILLE, N.C., Dec. 2, 2020 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing entry during the entire 2021 NASCAR Cup Series Season, starting at the season opener, the DAYTONA 500, at Daytona International Speedway in February 2021. Nurtec ODT was approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in February 2020 and is the first and only CGRP receptor antagonist available in an orally disintegrating tablet (ODT) designed for rapid onset o
Nov 30, 2020 08:00 am ET
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created...
Nov 22, 2020 09:31 pm ET
BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.
BioShin Limited announced today that the first patients were enrolled in its regional multi-center study, BHV3000-310, being conducted in China and Korea. BHV3000-310 is a double-blind, randomized trial evaluating the safety and efficacy of...
Nov 16, 2020 08:00 am ET
Value-based agreement between Prime Therapeutics and Biohaven aims to bring NURTEC™ ODT acute migraine treatment financial protection to health plans
EAGAN, Minn., Nov. 16, 2020 /PRNewswire/ -- Up to 55% of migraine patients do not have sufficient relief with currently available treatments.2 NURTEC™ ODT (rimegepant) can work quickly, returning patients to normal function in as little as one hour.1 NURTEC ODT's manufacturer, Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and pharmacy benefit manager Prime Therapeutics LLC (Prime) recently entered into a value-based contract agreement to help ensure that relief truly comes for patients.
Nov 16, 2020 06:30 am ET
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
NEW HAVEN, Conn., Nov. 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced that Dr. Richard Granstein, M.D., Chairman of Dermatology at Weill Cornell Medicine in New York City, will initiate an investigator-led clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis.
Nov 11, 2020 03:30 pm ET
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
NEW HAVEN, Conn., Nov. 11, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases including spinocerebellar ataxia, today announced its partnership with the National Ataxia Foundation (NAF) to help the nonprofit organization launch the NAF Drug Development Collaborative. As the first pharmaceutical industry member to commit support, Biohaven's partnership will help NAF accele
Nov 09, 2020 08:00 am ET
Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE™) at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, today announced the presentation of proof-of-concept data on KPMW101, an anti-tumor therapeutic...
Nov 09, 2020 07:00 am ET
Biohaven Reports Third Quarter 2020 Financial Results and Recent Business Developments
NEW HAVEN, Conn., Nov. 9, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the third quarter ended September 30, 2020, and provided a review of recent accomplishments and anticipated upcoming milestones.
Oct 30, 2020 06:23 pm ET
Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020
NEW HAVEN, Conn., Oct. 30, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming third quarter 2020 earnings call and webcast, reporting financial results for the quarter ended September 30, 2020 and provide a review of recent accomplishments and anticipated upcoming milestones, on Monday, November 9, 2020 at 8:30 a.m. ET.
Oct 29, 2020 12:50 pm ET
Kleo Pharmaceuticals Announces Data Presentation on Novel Conjugation Platform at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data from its multi-targeted antibody therapy enhancer (MATE™)...
Oct 14, 2020 07:30 am ET
U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine
NEW HAVEN, Conn., Oct. 14, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the preventive sNDA is set for 2Q2021.
Sep 21, 2020 08:00 am ET
Kleo Pharmaceuticals to Present at “Bioscience Pipeline & Innovation in Connecticut in the Age of COVID” Conference
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present today to local stakeholders at the Bioscience Pipeline &...
Sep 08, 2020 08:30 am ET
Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma
Kleo Pharmaceuticals, a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced today that its lead compound, KP1237, has received Orphan Drug designation from the U.S....
Aug 07, 2020 09:47 am ET
Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street
NEW HAVEN, Conn., Aug. 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced that it entered into a $500 million non-dilutive term loan financing facility with Sixth Street, a leading global investment firm.
Aug 07, 2020 09:40 am ET
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250 million in funding to advance the company’s CGRP receptor antagonist program through the development of...
Aug 07, 2020 09:37 am ET
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
NEW HAVEN, Conn. and NEW YORK, Aug. 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250 million in funding to advance the company's CGRP receptor antagonist program through the development of zavegepant (formerly known as vazegepant). The zavegepant program encompasses intranasal zavegepant as well as oral zavegepant for migraine prevention and non-migraine indications. In exchange for these funds, Royalty Pharma will obtain a 0.4% royalty on annual worldwide net sales of Nurt
Aug 05, 2020 05:00 pm ET
Biohaven Pharmaceutical To Report Second Quarter 2020 Financial Results And Recent Business Developments On August 10, 2020
NEW HAVEN, Conn., Aug. 5, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming second quarter 2020 earnings call and webcast, reporting financial results for the quarter ended June 30, 2020 and providing a review of recent accomplishments and anticipated upcoming milestones, on Monday, August 10, 2020 at 8:00 a.m. ET.
Aug 03, 2020 08:00 am ET
Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital
NEW HAVEN, Conn., Aug. 3, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced today that the first patients were enrolled in the HEALEY ALS Platform Trial, which is evaluating the efficacy of three treatments including verdiperstat in people with amyotrophic lateral sclerosis ("ALS"). Verdiperstat is a potential first-in-class, brain-penetrant, selective inhibitor of myeloperoxidase in development by Biohaven for the treatment of neurodegenerative diseases, including ALS and multiple system atrophy.
Jul 21, 2020 07:30 am ET
Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy
NEW HAVEN, Conn., July 21, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it has successfully completed enrollment in the M-STAR study, an international Phase 3 clinical trial evaluating the safety and efficacy of verdiperstat in multiple system atrophy (MSA). Verdiperstat is an investigational drug and potential first-in-class myeloperoxidase (MPO) inhibitor designed to target sources of neuroinflammation that contribute to brain cell death in neurodegenerative diseases including MSA and amyotrophic lateral sclerosis (ALS). Verdiperstat h
Jul 15, 2020 07:30 am ET
After Living with Migraine for Years, Khloé Kardashian Leads Biohaven's Take Back Today Campaign to Empower People with Migraine
NEW HAVEN, Conn., July 15, 2020 /PRNewswire/ -- Khloé Kardashian joins efforts with Biohaven Pharmaceuticals to launch the Take Back Today campaign to empower people with migraine to share their stories in an online community, learn about new ways to manage their disease and get back to what matters most – whether that is spending more time with family, friends, a favorite hobby or work. For more than 20 years, Khloé has experienced first-hand the debilitating impact of migraine, an often-misunderstood disease, which inspired her to join this campaign to help other people with migraine.  
Jul 08, 2020 07:30 am ET
Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients
Kleo Pharmaceuticals, a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that it has received a $5 million grant from the Bill...
Jun 24, 2020 07:00 am ET
Biohaven Announces Obsessive-Compulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program Update
NEW HAVEN, Conn., June 24, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today reported topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD). 
Jun 16, 2020 07:00 am ET
Biohaven Presents NURTEC™ (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting
NEW HAVEN, Conn., June 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that it presented data from 25 accepted abstracts demonstrating the efficacy, safety, tolerability and pharmacoeconomic value of NURTEC™ (rimegepant) at the 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting.
Jun 10, 2020 07:00 am ET
Biohaven Appoints Bob Hugin to its Board of Directors
NEW HAVEN, Conn., June 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of pharmaceutical industry leader Robert J. Hugin to its Board of Directors, effective immediately. Mr. Hugin previously served as the Chairman and Chief Executive Officer of Celgene Corporation where he was instrumental in the strategic growth and global expansion of the company. Celgene was ultimately acquired by Bristol-Myers Squibb in 2019 for a total equity value of approximately $74 billion.
Jun 01, 2020 04:05 pm ET
Kleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare Conference
Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, today announced that it will present at the Jefferies Virtual...
May 21, 2020 07:30 am ET
Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma
Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, and Celularity, Inc., a leading developer of allogeneic, or...
May 18, 2020 07:30 am ET
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
NEW HAVEN, Conn., May 18, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted abstracts demonstrating the efficacy, safety, tolerability, and pharmacoeconomic value of NURTEC (rimegepant) on the 2020 American Academy of Neurology (AAN) Science Highlights virtual platform. NURTEC™ ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist in an orally disintegrating tablet (ODT) approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine
May 15, 2020 07:33 am ET
Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society o
Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, today announced preclinical data for the company’s lead...
May 07, 2020 04:10 pm ET
Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments
NEW HAVEN, Conn., May 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended March 31, 2020, and provided a review of recent accomplishments and anticipated upcoming milestones.
Apr 27, 2020 07:30 am ET
Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East
NEW HAVEN, Conn., April 27, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Genpharm Services, a leading partner for innovative pharmaceuticals in Dubai, announced today an agreement to distribute NURTEC™ ODT (rimegepant) in the Middle East and Gulf countries. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.
Apr 16, 2020 05:42 pm ET
Biohaven Changing 2020 Annual Meeting Of Shareholders To Virtual-Only Meeting Format Due To COVID-19
NEW HAVEN, Conn., April 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that its Board of Directors has decided to hold the company's 2020 Annual Meeting of Shareholders on Thursday, April 30, 2020 at 10:00 a.m. Atlantic Time (9:00 a.m. Eastern Time) in a virtual-only meeting format due to the evolving nature of the COVID-19 pandemic and taking into account the guidance and protocols issued by public health and government authorities.
Apr 16, 2020 07:30 am ET
Biohaven Enters Into Partnership With Medison Pharma To Distribute NURTEC™ ODT In Israel
NEW HAVEN, Conn., April 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Medison Pharma, Israel's leading partner for innovative pharmaceuticals, announced today an agreement to distribute NURTEC™ ODT (rimegepant) in Israel. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.
Apr 09, 2020 07:30 am ET
Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection
NEW HAVEN, Conn., April 9, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it submitted Pre-IND/IND material to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of vazegepant, an intranasal, high-affinity calcitonin gene-related peptide (CGRP) receptor antagonist, for the treatment of COVID-19 infection associated pulmonary complications. The IND was approved by the Division of Pulmonary, Allergy, and Critical Care at FDA on April 8th and Biohaven was informed that the study may proceed immediately.  Vaze
Apr 07, 2020 07:30 am ET
Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT
NEW HAVEN, Conn., April 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced a collaboration with Cove, a company providing specialized care and access to innovative treatments for migraine sufferers via telemedicine services in the United States. The collaboration seeks to facilitate telemedicine evaluation for migraine sufferers while patients are increasingly looking to remote evaluations during this time of unprecedented decreased access to routine office visits.
Mar 31, 2020 07:33 am ET
Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy
NEW HAVEN, Conn., March 31, 2020 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that it has entered into a research collaboration with South Korea -based Green Cross LabCell (GCLC), a pioneer in the next generation of allogeneic, or "off-the-shelf" natural killer (NK) cell therapies, to rapidly advance testing of both advanced technology platforms in combination as a potential therapy for COVID-19 patients.
Mar 30, 2020 07:30 am ET
Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine
NEW HAVEN, Conn., March 30, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results in its randomized, placebo-controlled pivotal clinical trial (NCT03732638) evaluating the efficacy and safety of oral rimegepant 75 mg for the preventive treatment of migraine in both episodic and chronic migraine patients. The study met the primary endpoint, demonstrating a statistically significant reduction from baseline in monthly migraine days in patients treated with rimegepant compared with placebo. Those receiving rimegepant 75 mg every o
Mar 23, 2020 07:30 am ET
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
NEW HAVEN, Conn., March 23, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or, the "Company") today announced a successful end of Phase 2 clinical and nonclinical interaction with the U.S. Food and Drug Administration (FDA) for intranasal vazegepant for the acute treatment of migraine. The Company addressed all issues raised by the FDA and will advance the 10 mg dose of intranasal vazegepant into a double-blind, placebo-controlled Phase 3 clinical trial.  Biohaven previously reported that intranasal vazegepant 10 and 20 mg achieved statistical supe
Mar 18, 2020 07:30 am ET
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
NEW HAVEN, Conn., Mar. 18, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a biopharmaceutical company focused on the development and commercialization of innovative best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, announced today that the Company's myeloperoxidase (MPO) inhibitor, verdiperstat, received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of multiple system atrophy (MSA).
Nov 06, 2019 08:02 am ET
Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM™, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting
NEW HAVEN, Conn., Nov. 6, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that two abstracts have been accepted for presentation at the 61st annual American Society of Hematology (ASH) meeting and exposition being held December 7-10 in Orlando, FL.
Nov 05, 2019 06:30 am ET
Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole
NEW HAVEN, Conn., Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has completed enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease. An interim futility analysis examining standard cognitive assessments and volumetric magnetic resonance imaging (MRI) is expected before the end of 2019.
Nov 04, 2019 05:43 pm ET
Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company provided an update regarding the appointment of Thomas J. Lynch, Jr., MD, as Chairman of the Board at Kleo Pharmaceuticals. Biohaven's current ownership interest in outstanding stock of Kleo is 41.9%.
Nov 01, 2019 04:15 pm ET
Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments
NEW HAVEN, Conn., Nov. 1, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended September 30, 2019, and provided a review of recent accomplishments and anticipated milestones.
Oct 28, 2019 07:30 am ET
Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
NEW HAVEN, Conn., Oct. 28, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurologic and neuropsychiatric diseases, today announced that it has completed enrollment in its pivotal Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized anxiety disorder (GAD). This multicenter, randomized, placebo-controlled, trial enrolled over 880 patients in less than nine months.
Sep 18, 2019 07:30 am ET
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
NEW HAVEN, Conn., Sept. 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and neuropsychiatric diseases, announced today that the Company's myeloperoxidase (MPO) inhibitor, verdiperstat, has been selected as an investigational therapy in the first Amyotrophic Lateral Sclerosis (ALS) platform trial, an innovative program designed by the Sean M. Healey & AMG Center for ALS at Mass General to help accelerate a path to n
Sep 12, 2019 09:00 am ET
Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases
According to a recent market research report published by Grand View Research, a consulting and advisory service firm that provides comprehensive, research-based views crucial for building business intelligence and overcoming market challenges,...
Sep 10, 2019 07:30 am ET
Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For T
NEW HAVEN, Conn., Sept. 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, today announced completion of enrollment in its Phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered vazegepant (formerly BHV-3500) for the acute treatment of migraine. Vazegepant is a novel, structurally unique, third-generation calcitonin gene-related peptide (CGRP) receptor antagonist and the second product candidate in
Sep 09, 2019 07:30 am ET
Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference
NEW HAVEN, Conn., Sept. 9, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it presented expanded data and post-hoc analyses from its long term clinical study (BHV3000-201) demonstrating clinically important benefits of rimegepant on migraine-specific disability and quality of life in the late breaking oral and poster sessions at the International Headache Conference in Dublin, Ireland.
Aug 09, 2019 06:47 am ET
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
NEW HAVEN, Conn., Aug. 8, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended June 30, 2019, and provided a review of recent accomplishments and anticipated milestones.
Aug 08, 2019 05:02 pm ET
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
NEW HAVEN, Conn., Aug. 8, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended June 30, 2019, and provided a review of recent accomplishments and anticipated milestones.
Aug 07, 2019 07:30 am ET
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
NEW HAVEN, Conn., Aug. 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases today reported completion of enrollment in its pivotal Phase 3 preventive treatment of migraine trial with rimegepant, its lead oral calcitonin gene-related peptide (CGRP) receptor antagonist product candidate.
Jul 31, 2019 07:30 am ET
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
NEW HAVEN, Conn., July 31, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and neuropsychiatric diseases, announced today that it enrolled the first patient in a Phase 3 clinical trial to evaluate the efficacy and safety of verdiperstat in subjects with Multiple System Atrophy ("MSA").
Jul 22, 2019 07:30 am ET
Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
NEW HAVEN, Conn., July 22, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease, is progressing on timelines with more than 400 subjects enrolled (for screening) and over 180 subjects randomized to study treatment (troriluzole or placebo). The trial is expected to be fully enrolled befor
Jul 19, 2019 06:10 pm ET
Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug
NEW HAVEN, Conn., July 19, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has received a Complete Response Letter (CRL) from the FDA for the 505(b)2 application seeking approval for NURTEC™ (riluzole) for ALS.
Jul 15, 2019 07:30 am ET
Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
NEW HAVEN, Conn., July 15, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet (ODT) for the acute treatment of migraine. These data show that compared to placebo, patients treated with a single dose of the rimegepant ODT formulation experienced rapid and sustained clinical benefits.
Jul 11, 2019 07:30 am ET
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), has launched a campaign called 'Demand More' highlighting what patients want and need from an acute treatment of migraine in their own words. Patients define real relief from migraine as fast and reliable pain relief, with the ability to return to function quickly and a sustained effect without the need for repeat dosing. Patients want more from their acute treatment, desiring new options with fewer side effects. The company introduced the campaign to healthcare providers at the 61st An
Jul 11, 2019 07:30 am ET
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multipl
NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced it will present 16 scientific presentations (oral and poster) highlighting new efficacy and safety data for rimegepant from Biohaven's robust clinical development program at the American Headache Society (AHS) Annual Scientific Meeting in Philadelphia, July 11-14, 2019. Notably, Biohaven will be presenting results from the rimegepant Zydis® oral fast-dissolve tablet (ODT) Phase 3 trial, new analyses across the three Phase 3 trials, results from the rimegepant long-term s
Jul 10, 2019 05:00 pm ET
Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
NEW HAVEN, Conn., July 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that positive results from a Phase 3 pivotal clinical trial of rimegepant, Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine, are published in the July 12, 2019 issue of the New England Journal of Medicine (NEJM). These data show that, compared to placebo, patients treated with a single dose of oral rimegepant 75mg experienced superior, rapid pain freedom and freedom from the most bothersome migraine
Jul 01, 2019 07:30 am ET
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
NEW HAVEN, Conn., July 1, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that the first patient has been enrolled in a Phase 2 clinical trial assessing the efficacy and safety of rimegepant in treatment refractory trigeminal neuralgia. 
May 07, 2019 11:30 pm ET
Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migrai
NEW HAVEN, Conn., May 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced additional safety and preliminary efficacy results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant. Based upon this interim analysis of Study BHV3000-201 (NCT03266588 or "Study 201"), database cutoff of February 20, 2019, rimegepant was well tolerated with long-term dosing up to one year in patients with migraine. Thus far, 105,192 doses of rimegepant 75 mg was administered up to once dai
May 07, 2019 11:15 pm ET
Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
NEW HAVEN, Conn., May 7, 2019 /PRNewswire/ -- (NYSE: BHVN) - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced continued progress in its glutamate modulating platform with enrollment expected to complete in three Phase 2/3 clinical trials of troriluzole in Alzheimer's disease, generalized anxiety disorder and obsessive-compulsive disorder by the end of 2019.  Enrollment in the spinocerebellar ataxia Phase 3 clinical trial is expected to complete by the first quarter of 2020.  In addition, the first Phase 3 trial from the company's myeloperoxidase (MPO) inhibition pla
May 07, 2019 06:55 am ET
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
NEW HAVEN, Conn., May 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, reported financial results and business updates for the quarter ended March 31, 2019.
May 03, 2019 07:30 am ET
Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event
NEW HAVEN, Conn., May 3, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that results from the pivotal rimegepant Zydis® ODT Phase 3 clinical trial will be presented as a late-breaking oral presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, May 4-10, 2019. This presentation is 1 of only 11 abstracts accepted as part of the Emerging Science (Late-Breaking) program, and the only CGRP-targeting migraine data accepted for the Late-Breaking session. Rimegepant is an oral, single-dose, selective and potent sm
Apr 03, 2019 07:30 am ET
Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience
NEW HAVEN, Conn., April 3, 2019 /PRNewswire/ -- (NYSE: BHVN) - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of William "BJ" Jones as Chief Commercial Officer, Migraine and Common Diseases. Mr. Jones will have oversight of the commercial development of the company's calcitonin gene-related peptide (CGRP) receptor antagonist platform portfolio and glutamate portfolio in Alzheimer's Disease (AD), obsessive compulsive disorder (OCD), and generalized anxiety disorder (GAD). Mr. Jones will report directly to Vlad Coric M.D., Chief Executive Officer.
Apr 01, 2019 07:30 am ET
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
NEW HAVEN, Conn., April 1, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, today announced that it enrolled the first patient in a Phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered BHV-3500 for the acute treatment of migraine. BHV-3500 is a novel, structurally distinct, third-generation calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Biohaven.
Mar 18, 2019 07:30 am ET
Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application
NEW HAVEN, Conn., March 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, today announced that the company has purchased a U.S. Food and Drug Administration (FDA) priority review voucher (PRV) to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019. The PRV entitles the holder to designate an NDA for priority review and provides for an expedited 6
Mar 14, 2019 07:30 am ET
Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
NEW HAVEN, Conn., March 14, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in Spinocerebellar Ataxia (SCA).

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.